RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial

Gustavo Lopardo; Waldo H. Belloso; Esteban Nannini; Mariana Colonna; Santiago Sanguineti; Vanesa Zylberman; Luciana Muñoz; Martín Dobarro; Gabriel Lebersztein; Javier Farina; Gabriela Vidiella; Anselmo Bertetti; Favio Crudo; Maria Fernanda Alzogaray; Laura Barcelona; Ricardo Teijeiro; Sandra Lambert; Darío Scublinsky; Marisa Iacono; Vanina Stanek; Rubén Solari; Pablo Cruz; Marcelo Martín Casas; Lorena Abusamra; Héctor Lucas Luciardi; Alberto Cremona; Diego Caruso; Bernardo de Miguel; Santiago Perez Lloret; Susana Millán; Yael Kilstein; Ana Pereiro; Omar Sued; Pedro Cahn; Linus Spatz; Fernando Goldbaum

EClinicalMedicine (2021) - Comments
doi: 10.1016/j.eclinm.2021.100843 issn: 2589-5370 pubmed: 33870149

Gustavo Lopardo, Waldo H. Belloso, Esteban Nannini, Mariana Colonna, Santiago Sanguineti, Vanesa Zylberman, Luciana Muñoz, Martín Dobarro, Gabriel Lebersztein, Javier Farina, Gabriela Vidiella, Anselmo Bertetti, Favio Crudo, Maria Fernanda Alzogaray, Laura Barcelona, Ricardo Teijeiro, Sandra Lambert, Darío Scublinsky, Marisa Iacono, Vanina Stanek